Skip to main content
. Author manuscript; available in PMC: 2012 May 14.
Published in final edited form as: Virology. 2010 Mar 20;401(2):228–235. doi: 10.1016/j.virol.2010.02.029

Figure 1. EBOV neutralizing antibodies bind natural GP products of infection.

Figure 1

(A) EBOV GP viral pseudotypes were incubated with various concentrations of mouse 6D8, 6D3 and 13C6, human KZ52, and monkey JP3K11 for one hour prior to infection of HUVEC cells. Luciferase activity was read 72 hours post infections and graphed as % infection relative to infection in the absence of antibody. Error bars represent ± SEM. (B) Competitive IP for natural GP products of infection: WT or CatL-processed (GPCatL) GP-bearing pseudovirus and sGP. IP material control (Input) and IP samples were analyzed by SDS-PAGE and Western immunoblotting using JCB antibody reagent for detection. Experiments were performed independently at least three times with similar results.